PRESS RELEASE published on 05/14/2024 at 22:05, 1 year 8 months ago Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress
Published on 02/04/2026 at 02:15, 4 hours 35 minutes ago Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 6 hours 50 minutes ago Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 7 hours 20 minutes ago FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 7 hours 38 minutes ago Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 8 hours 20 minutes ago Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million
Published on 02/04/2026 at 02:05, 4 hours 44 minutes ago Saudi Arabia Preparing for AlUla Emerging Market Economies Conference to be Held February 8-9, 2026
Published on 02/04/2026 at 00:42, 6 hours 7 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3X - Initial Director's Interest Notice
Published on 02/03/2026 at 20:57, 9 hours 52 minutes ago EQS-Adhoc: tick Trading Software AG adjusts forecast for the current 2025/2026 fiscal year
Published on 02/03/2026 at 20:36, 10 hours 13 minutes ago Freelance.com: Agenda de communication financière 2026-2027
Published on 02/03/2026 at 18:00, 12 hours 50 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 13 hours 5 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 02/03/2026 at 17:45, 13 hours 5 minutes ago Chiffre d’affaires 2025 en croissance à 11,2 M€ (+5%)
